VYNE News and Press, VYNE Therapeutics Inc Com From 07/19/21

BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficac...

VYNE Therapeutics Inc. (NASDAQ:VYNE) traded at a new 52-week low today of $2.63. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 934,000 shares. There is potential upside of 101.1% for shares of VYN...

VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at a new 52-week low of $2.68. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 921,000 shares. VYNE Therapeutics Inc is a biopharmaceutical company ...

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock. For further details see: VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2 nd Ann...

Alfi (ALF) +35%.SemiLEDs Corporation (LEDS) +19%.Protagenic Therapeutics (PTIX) +18%.Party City Holdco (PRTY) +12% on Q1 results.BioNTech SE (BNTX) +9% on Q1 results.Aptorum Group Limited (APM) +8%.VYNE Therapeutics (VYNE) +8%.Inovio Pharmaceuticals (INO) +8% on positive data f...

iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...

Image source: The Motley Fool. VYNE Therapeutics Inc. (NASDAQ: VYNE) Q1 2021 Earnings Call May 06, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: VYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Call Transcript

VYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Michael Wood – LifeSci Advisors Dave Domzalski – President and Chief Executive Officer Andrew Saik – Chief Financial Officer Matt Wiley – Chief Commercial Off...

Shares of VYNE Therapeutics (NASDAQ: VYNE) were crashing 18.1% lower as of 11:35 a.m. EDT on Thursday. The big decline came after the company announced its first-quarter results before the market opened. VYNE reported Q1 revenue of $4.1 million, up from $1.8 million in the prior...